RPEP-16636 · 2026Across guidelines from the AAP, WHO, NICE, and Polish pediatric bodies, GLP-1 receptor agonists — specifically liraglutide and semaglutide — are now recommended as adjunctive pharmacotherapy for carefully selected adolescents with severe obesity and significant comorbidities. Family-based lifestyle intervention remains the cornerstone of care across all frameworks, but the review reveals clinically important differences in diagnostic thresholds, risk stratification approaches, and comorbidity screening recommendations between organizations.
Łuczak, Paweł M; Perediatkiewicz, Jakub; Liszka, Paweł; Puchalski, Konrad; Patrzykąt, Klaudia M; Olejnik-Chlewicka, Klaudia M; Urbański, Wojciech; Zasiadła, Marta; Brodowski, Jakub; Ogórek, Agata ·
RPEP-16637 · 2028The conference identified several key conclusions for managing coexisting heart failure (HF) and chronic kidney disease (CKD):
SGLT2 inhibitors, RAAS inhibitors, finerenone, and GLP-1 receptor agonists all show benefits in patients with both HF and CKD, though evidence in advanced CKD remains limited. Natriuretic peptide biomarkers require careful interpretation in CKD patients, and CKD-specific diagnostic thresholds for HF are needed.
Critically, small declines in kidney function after initiating guideline-directed HF therapies are generally hemodynamic in nature and not associated with poor outcomes — meaning they should not trigger treatment discontinuation. The conference called for more integrated cardio-renal management approaches and clinical trials that include relevant kidney endpoints.
Lam, Carolyn S P; Bozkurt, Biykem; Cherney, David Z I; Ezekowitz, Justin A; Jardine, Meg J; Khan, Sadiya S; Madero, Magdalena; Sarnak, Mark J; Ter Maaten, Jozine M; Cheung, Michael; King, Jennifer M; Grams, Morgan E; Jadoul, Michel; Bansal, Nisha ·